Drug Profile
PL 1
Alternative Names: PL-1Latest Information Update: 05 Sep 2023
Price :
$50
*
At a glance
- Originator Changchun ProteLight Pharmaceutical and Biotechnology
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Bacterial infections in China (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Bacterial-infections in China (Parenteral, Injection)
- 08 Jul 2016 Preclinical trials in Bacterial infections in China (Parenteral)